孟鲁司特钠联合布地奈德治疗支气管哮喘临床疗效分析

Clinical Efficacy of Montelukast Sodium Combined with Budesonide in the Treatment of Bronchial Asthma

目的分析孟鲁司特钠+布地奈德治疗支气管哮喘的应用价值及临床疗效。方法择取本院在2017年8月至2018年8月所收治的80例支气管哮喘患者进行研究,根据中心分组方式将患者归为试验组(n=40)与参照组(n=40)。参照组实施布地奈德治疗,试验组实施孟鲁司特钠片联合布地奈德治疗,对比两组患者的临床疗效、治疗前后免疫球功能变化、肺功能改善情况及不良反应发生率。结果试验组总有效率为95.00%明显高于参照组的77.50%,P<0.05;两组干预前CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)指标对比未见差异(P>0.05),治疗后参照组和试验组的CD_(3)^(+)与CD_(4)^(+)水平均比治疗前高,CD_(8)^(+)水平均比治疗前低,试验组CD_(3)^(+)与CD_(4)^(+)水平均高于参照组,CD_(8)^(+)水平低于参照组,P<0.05;两组干预前第1秒用力呼气容积、用力肺活量指标对比未见差异(P>0.05),试验组的第一秒用力呼气容积、用力肺活量水平均高于参照组,P<0.05;两组干预前TNF-α、IL-6、IL-8指标对比未见差异(P>0.05);干预后,试验组指标数值低于参照组,P<0.05;试验组MAP指标给药前与给药后1 d对比参照组,未见差异,P>0.05,HR指标给药前试验组与参照组对比未见差异,P>0.05;其余时间段对比,试验组指标优于参照组,(P<0.05)。对比两组不良反应发生率,P>0.05。结论和单纯应用布地奈德对比,孟鲁司特钠片与布地奈德联合治疗支气管哮喘能够改善患者的机体免疫力,加强肺功能,减少不良反应发生率,其临床效果确切。

Objective To analyze the application value and clinical efficacy of montelukast sodium+budesonide in the treatment of bronchial asthma.Methods Eighty patients with bronchial asthma admitted to our hospital from August 2017 to August 2018 were enrolled.The patients were classified into the experimental group(n=40 cases)and the reference group(n=40)according to the central grouping method.The reference group was treated with budesonide.The experimental group was treated with montelukast sodium tablets combined with budesonide.The clinical efficacy,immunoglobulin function,lung function improvement and adverse reaction rate were compared between the two groups.Results The total effective rate of the experimental group was 95.00%higher than that of the reference group(77.50%),P<0.05.There was no difference in CD_(3)^(+),CD_(4)^(+),CD_(8)^(+)index comparison between the two groups before intervention(P>0.05),after treatment,the CD_(3)^(+)and CD_(4)^(+)levels in the reference group and the experimental group were higher than before treatment,and the CD_(8)^(+)level was lower than before treatment.The test group CD_(3)^(+),CD_(4)^(+)level was higher than the reference group,and the CD_(8)^(+)level was lower than the reference group,P<0.05.There was no difference in the index of forced expiratory volume and forced vital capacity in the first second before the intervention between the two groups(P>0.05),the forced expiratory volume and forced vital capacity in the first second of the experimental group were higher than the reference group,P<0.05;there was no difference in the comparison of TNF-α,IL-6 and IL-8 indexes between the two groups before intervention(P>0.05);after intervention,the index values of the experimental group were lower than those of the reference group,P<0.05;the MAP index of the experimental group was compared with that before administration.1 day after administration,compared with the reference group,there was no difference,P>0.05,the HR index before administration was compared with the reference group,there was no difference,P>0.05;in the rest of the time period,the test group index was better than the reference group,(P<0.05).The incidence of adverse reactions in the two groups was compared,P>0.05.Conclusion Compared with budesonide alone,the combination of montelukast sodium and budesonide in the treatment of bronchial asthma can improve the body's immunity,strengthen lung function and reduce the incidence of adverse reactions.The clinical effect is clear.